News & Events

News July 29, 2026

BrainsWay to Report Second Quarter 2026 Financial Results on August 12, 2026

BURLINGTON, Mass. and JERUSALEM, July 29, 2026 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ &...

Events, News September 30 - September 30, 2026

Rotterdam, The Netherlands

ISAM Global Addiction Therapeutics Innovation Day (GATID) 2026

BrainsWay will be participating in the ISAM Global Addiction Therapeutics Innovation Day (GATID), taking...

Events, News September 24 - September 25, 2026

Seville, Spain

4th Conference on Advances in Neuromodulation

BrainsWay will be participating in the IV Jornadas de Actualizaciones en Neuromodulación, taking place...

News July 20, 2026

BrainsWay Announces Strategic Investment in Radial Health, Inc.

BrainsWay continues to actively evaluate similar investments in leading North American mental health...

News July 16, 2026

BrainsWay Announces Minority-Stake Investment in Sound Minds Behavioral

Investment further supports BrainsWay’s strategy of partnering with growth-oriented mental health...

News June 29, 2026

BrainsWay Presents Positive Data from Largest Real-World Study of Deep TMS™ in Patients with Comorbid PTSD and Major Depressive Disorder

Nearly half of individuals diagnosed with PTSD also meet criteria for major depressive disorder (MDD),...

News June 10, 2026

BrainsWay Presents First SWIFT™ Accelerated Deep TMS 12-Month Durability Data at Clinical TMS Society Annual Meeting

Preliminary Data Analysis Reveals Over 80% Remission Rate One Year after Accelerated Deep TMS Treatment,...

News May 18, 2026

BrainsWay Announces Minority-Stake Investment in Hopemark Health

Investment in provider servicing clinics in Illinois is latest in series of similar transactions by BrainsWay...

News May 13, 2026

BrainsWay Reports First Quarter 2026 Financial Results and Operational Highlights

Revenue grew approximately 35% year-over-year to $15.5 million for Q1 2026 Net income increased by over...

News April 29, 2026

BrainsWay to Report First Quarter 2026 Financial Results on May 13, 2026

BURLINGTON, Mass. and JERUSALEM, Israel, April 29, 2026 — BrainsWay Ltd. (NASDAQ & TASE: BWAY)...

News April 15, 2026

BrainsWay Highlights Growing U.S. Payer Support for Nurse Practitioner-Administered Transcranial Magnetic Stimulation (TMS) Therapy

Growing payer acceptance of nurse practitioner administration of Deep TMS is expected to expand access...

News March 26, 2026

BrainsWay Completes Additional $6 Million Milestone-Based Investment in Neurolief Ltd. Following FDA Approval of Proliv™Rx System for MDD

BURLINGTON, Mass. and JERUSALEM, Israel, March 26, 2026 – BrainsWay Ltd. (NASDAQ & TASE: BWAY)...

News March 19, 2026

BrainsWay Completes Revenue-Based Milestone Investment into Axis Integrated Mental Health

BrainsWay’s investment is part of its ongoing strategy to partner with leading U.S. mental health providers...

News March 11, 2026

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

BrainsWay Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Q4 Revenue...

News March 4, 2026

Landmark Data Validate BrainsWay’s SWIFT™ Deep TMS, Beginning a New Era in Depression Treatment

BURLINGTON, Mass. and JERUSALEM, March 4, 2026 — BrainsWay Ltd. (NASDAQ & TASE: BWAY) unveiled...

News February 17, 2026

BrainsWay Announces Change in ADS-to-Ordinary Share Ratio

Change in ADS ratio aimed at simplifying comparisons to ordinary shares traded on the Tel Aviv Stock...

News January 12, 2026

BrainsWay Announces FDA Approval of Neurolief’s Proliv™Rx Neuromodulation System for Major Depressive Disorder (MDD)

BrainsWay’s strategic investment in Neurolief paved the way for the first and only FDA approved at-home...

News December 22, 2025

BrainsWay Announces First Coverage Policy for Accelerated Deep TMS™

New Premera Blue Cross policy extends to both adolescent and adult depression patients BURLINGTON, Mass....